Transcranial Magnetic Stimulation in Smokers: an Examination of Mediating Neural Pathways.
Launched by KENT STATE UNIVERSITY · Dec 6, 2022
Trial Information
Current as of January 21, 2025
Completed
Keywords
ClinConnect Summary
The study will include functional magnetic resonance imaging at baseline as well as demographic, psychological, and tobacco use assessments. Following initial assessment, participants will undergo one active rTMS session (20 Hz rTMS, 900 pulses per session, applied to left DLPFC). The outcome session will include assessments repeated from baseline.
The current proposal will examine the following aims. Aim 1: To test the potential for active rTMS to improve cognitive control of craving. Hypothesis: Active rTMS (compared to sham rTMS) will result in significant improvement in control over cr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Smokers endorsing atleast moderate dependence (total Fagerstrom for Cigarette Dependence score \> 4)
- • Endorsing no specific plan to quit smoking in the next 3 months.
- • Must meet safety guidelines for application of rTMS
- • 18-60 years of age
- • Smoked cigarettes regularly for at least one year
- • Currently smoke at least 10 cigarettes per day
- • Have a carbon monoxide (CO) level greater or equal to 10 ppm
- • Currently be using no other nicotine products.
- Exclusion Criteria:
- • Subjects will be excluded if they meet criteria for current alcohol (moderate - severe), current substance dependence, current affective disorder (depression, dysthymia, or mania) or current psychotic symptoms as assessed by the (MINI) International Neuropsychiatric Exam
- • Are currently pregnant or lactating, or intend to become pregnant
- • Have a health condition for which rTMS is contraindicated
- • Submit a urine drug screen positive for illicit substances or substance misuse.
About Kent State University
Kent State University is a distinguished public research institution located in Kent, Ohio, renowned for its commitment to academic excellence and innovation in various fields, including health sciences. As a clinical trial sponsor, the university leverages its extensive resources, expertise, and collaborative networks to advance medical research and improve patient outcomes. Kent State University prioritizes ethical standards and regulatory compliance in its clinical trials, fostering a rigorous environment for the development of new therapies and interventions. Through its dedication to research and community engagement, the university aims to contribute significantly to the advancement of healthcare knowledge and practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials